Recent studies have demonstrated excellent responses to ICIs and/or their combinations regimen in a subset of patients with high levels of PD-L1 expression in the tumor, CDK12 mutations, high levels of TMB, or high levels of microsatellite instability (MSI), and low levels of mismatch repair (dMMR). The gene discussed is CD274; the disease is neoplasm.